Generic Name and Formulations:
Naltrexone HCl 50mg; scored tabs.
Indications for REVIA:
Adjunct in treatment of alcohol or narcotic dependence.
Confirm 7–10 day opioid-free period, if questionable do Narcan challenge test (see literature). ≥18yrs: Alcoholism: 50mg daily. Narcotic dependence: Initially 25mg, if no withdrawal symptoms increase to 50mg daily; alternative dosing schedules: see literature.
<18yrs: not recommended.
Concomitant opioids, current opioid dependence, or acute opioid withdrawal. Failed Narcan challenge test or (+) urine screen for opioids. Acute hepatitis. Liver failure.
Liver disease. Monitor liver function. Warn patients of danger of attempting to overcome opiate blockade. Severe renal dysfunction. Possible acute abstinence syndrome. Depression. Suicidal ideation. Pregnancy (Cat.C). Nursing mothers.
Thioridazine increases sedation. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics). Disulfiram.
Hepatotoxicity, withdrawal reactions; others, see literature.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|